KM1 + chemotherapy

KM1 + chemotherapy is an investigational combination therapy comprising the oncolytic vaccinia virus KM1 and standard-of-care chemotherapy agents, currently being evaluated for the treatment of recurrent or refractory ovarian cancer. KM1, developed by Huayao Kangming Biological, is an oncolytic vaccinia virus designed to selectively infect, replicate within, and lyse tumor cells while simultaneously remodeling the immunosuppressive tumor microenvironment to stimulate a systemic anti-tumor immune response. In clinical protocols led by Tongji Hospital, KM1 is administered via intraperitoneal infusion, followed by a physician's choice of chemotherapy—which may include platinum agents (carboplatin, cisplatin), taxanes (paclitaxel, docetaxel, or nab-paclitaxel), gemcitabine, or pegylated liposomal doxorubicin, with or without bevacizumab. This dual approach aims to combine the direct viral oncolysis and immune-priming effects of KM1 with the established cytotoxic activity of chemotherapy to overcome resistance in advanced ovarian malignancies.

Other names

KM1 oncolytic vaccinia virus combined with chemotherapyKM-1 oncolytic vaccinia virus combined with chemotherapyKM 1 oncolytic vaccinia virus combined with chemotherapy